| Document |
Document Title |
|
WO/2020/232247A1 |
Provided herein, in one aspect, is a method of preventing or delaying the onset of clinical type 1 diabetes (T1D), comprising: providing a non-diabetic subject who is at risk for T1D; determining that the non-diabetic subject (1) is subs...
|
|
WO/2020/228577A1 |
Provided are a pyridazinone derivative and the use thereof. By selecting specific modification groups of the pyridazinone derivative provided in the present invention having a structure as shown in formula (I), the results show that the ...
|
|
WO/2020/229443A1 |
The present invention relates to a compound and a composition for use in the treatment of premenstrual syndrome and/or premenstrual dysphoric disorder.
|
|
WO/2020/227549A1 |
Disclosed herein are compounds of Formula (I) or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IlIa, lIIb, IlIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is ...
|
|
WO/2020/172686A9 |
IAPP peptides which inhibit the aggregation of human Islet Amyloid Polypeptide and their use in inhibiting amyloid fibril formation.
|
|
WO/2020/222366A1 |
The present invention provides: a health functional food composition which is for promoting height growth and includes a Humulus japonicus extract or ground Humulus japonicus as an active ingredient; and a composition which is for promot...
|
|
WO/2020/218517A1 |
Disclosed is a medicinal preparation that is in the form of granules each comprising a core particle and a coating layer coating the core particle, wherein: the core particle comprises a drug, a first core particle component, a second co...
|
|
WO/2020/217170A1 |
An extended release formulation is provided for use in a method for the treatment of Central Precocious Puberty (CPP) in pediatric patients 2 years of age or older. The extended release formulation comprises leuprolide or a pharmaceutica...
|
|
WO/2020/218450A1 |
The present invention addresses the problem of providing a novel peptide which can treat, prevent or ameliorate anorexia. The present invention provides a peptide described in any one of the following items (1) to (3). (1) A peptide co...
|
|
WO/2020/219872A1 |
The present invention relates to methods and compositions comprising a miR-10a-5p or miR-10b-5p mimic for treatment of gastrointestinal motility disorders, obesity and diabetes.
|
|
WO/2020/211571A1 |
A soil preparation, which is prepared from sterilized soil and oral probiotics or auxiliary materials, and an application of the soil preparation in preparing a drug for preventing and treating neuroendocrine disorder-related diseases.
|
|
WO/2020/210339A1 |
The present invention is related to compounds of structure (I) as heme oxygenase 1 (HMOX 1) inducers. (Formula I) The present invention is also related a method of controlling the activity or the amount, or both the activity and the amou...
|
|
WO/2020/210726A1 |
Methods and cellular markers useful for methods of diagnosing autoimmune disease, including type 1 diabetes (T1D) and disease progression in T1D patients, as well as identifying treatments for and monitoring treatment of patients with T1...
|
|
WO/2020/204117A1 |
Provided is a pharmaceutical composition which contains 3-{[(2S)-2-amino-2-carboxyethyl]carbamoylamino}-5-chloro-4-m
ethylbenzene sulfonic acid, a pharmaceutically acceptable salt thereof, or a solvate thereof, has a pH of at most 8.0, a...
|
|
WO/2020/204152A1 |
The present invention addresses the problem of providing a new drug for preventing, suppressing advance of symptoms, suppressing recurrence, or treating autoimmune disease. As a result of diligent studies, the inventors of the present ...
|
|
WO/2020/205803A1 |
Disclosed herein are segmented EVA Rings that contain progesterone that can be used to prevent preterm birth in subjects with a shortened cervix or to treat luteal phase deficiency or as luteal phase support.
|
|
WO/2020/194052A1 |
Provided herein are pharmaceutical compositions that are useful for the treatment of diabetes and associated conditions, diseases, and disorders. The compositions comprise a) a dipeptidyl peptidase IV (DPPIV) inhibitor such as sitaglipti...
|
|
WO/2020/194046A1 |
Pharmaceutical compositions useful in the treatment of metabolic disorders including diabetes, the compositions comprising a) a dipeptidyl peptidase IV (DPP IV) inhibitor such as sitagliptin, b) a biguanide such as metformin, and c) a su...
|
|
WO/2020/193652A1 |
The present disclosure provides methods for treating chronic kidney disease, comprising administering to a patient in need thereof, a therapeutically effective amount of canagliflozin; wherein the patient is diagnosed with Type II diabet...
|
|
WO/2020/196946A1 |
One aspect of the present disclosure relates to a novel long-acting fatty acid-binding gonadotrophin-releasing hormone (GnRH) derivative of GnRH and a pharmaceutical composition comprising same. The present disclosure is expected to grea...
|
|
WO/2020/198712A1 |
The present disclosure generally relates to pharmaceutical compositions and combinations comprising an androgen receptor N-terminal domain inhibitor or an inhibitor and a second therapeutically active agent, such as an CDK4/6 inhibitor, ...
|
|
WO/2020/191002A1 |
Disclosed herein are methods of treating a disease or disorder characterized by an increased secretion of adrenocorticotropic hormone (e.g., Cushing's disease). Also disclosed herein are methods of identifying compounds for use in treati...
|
|
WO/2020/186108A1 |
The present specification provides compositions of β-endorphin and adrenocorticotropic hormone (ACTH). These compositions are useful in methods of treating disease.
|
|
WO/2020/178273A1 |
The present invention relates to a long-acting growth hormone or a pharmaceutical formulation comprising such long-acting growth hormone for use in a method of treating growth hormone deficiency with improved outcomes.
|
|
WO/2020/180942A1 |
Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, a syndrome due to androgen excess, and/...
|
|
WO/2020/178074A1 |
New administration regimens of the T4 thyroid hormone are described, characterized by the use of alcohol-free, water-glycerol solutions of said hormone, administered at short temporal distance, i.e. within less than 30 minutes, typically...
|
|
WO/2020/180624A1 |
Compounds are provided having the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein A, X1, X2, Q, R1, R2 and n are as defined herein. Such compounds function ...
|
|
WO/2020/173739A1 |
The present invention discloses compounds according to Formula I: wherein R1, R2, R3a, R3b, Het, X and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compos...
|
|
WO/2020/172728A1 |
The present invention relates to the production of a biologically active recombinant equine chorionic gonadotropin (reCG), to a veterinary composition comprising the reCG, and to the use of the reCG or of the composition comprising reCG....
|
|
WO/2020/172501A1 |
Methods and compositions are disclosed for diagnosing a patient suspected of suffering from, and for treating a patient suffering from, a disorder such as hypercortisolemia, metabolic syndrome, pre-diabetes, diabetes, Cushing's syndrome,...
|
|
WO/2020/172640A1 |
Nonhormonal unisex contraceptive products, compositions, formulations and methods of use comprise an effective amount of a targeted mild mitochondria uncoupler.
|
|
WO/2020/169069A1 |
A compound of formula (I) or (Ia), or a tautomer or a pharmaceutically acceptable salt thereof is provided. Compounds of formula (II) to (V), or a tautomer or a pharmaceutically acceptable salt thereof are also provided. These compounds ...
|
|
WO/2020/163918A1 |
The present invention relates to pharmaceutical compositions for the treatment or prevention of symptoms associated with endocrine disturbances, such as hot flashes. The pharmaceutical compositions comprise a tricyclic amino containing c...
|
|
WO/2020/166592A1 |
A compound or represented by formula (1) or a salt thereof (in the formula, R1 represents a hydrogen atom or a sulfonyl group, and Z represents a group represented by formula (Z-1), etc.).
|
|
WO/2020/165087A1 |
A liquid pharmaceutical formulation, wherein the pharmaceutical formulation comprises a PTH conjugate, a buffering agent, an isotonicity agent, a preservative and optionally an antioxidant and wherein the PTH conjugate comprises a PTH mo...
|
|
WO/2020/163890A1 |
The present invention relates to pharmaceutical compositions for the treatment or prevention of symptoms associated with endocrine disturbances, such as hot flashes. The pharmaceutical compositions comprise a tricyclic amino containing c...
|
|
WO/2020/163026A1 |
Unusual and unexpectedly stable aqueous suspension formulation and water dispersible dry composition of the following formula (I) compounds. It causes little or no injection site irritation and has superior properties over non-aqueous fo...
|
|
WO/2020/163642A1 |
The present invention provides a compound of formula (I) or a salt thereof: (F ormula (I)) wherein X, L, V, R1, R2, R3 and R4, are as defined herein. The claimed compounds inhibit the enzyme 11-hydroxysteroid dehydrogenase type 2 (11-HSD...
|
|
WO/2020/161543A1 |
Methods and compositions for controlling hyperparathyroidism are disclosed.
|
|
WO/2020/160123A1 |
A stable liquid formulation for parenteral administration that includes levothyroxine or a pharmaceutically acceptable salt thereof. The formulation includes a low concentration of an antioxidant, an amino acid as a pH adjuster and a sta...
|
|
WO/2020/160118A1 |
The invention relates to parathyroid hormone (PTH) variants and pharmaceutical compositions comprising same. The invention further relates to PTH compositions with improved serum half-life and peak-trough ratios, and methods of controlli...
|
|
WO/2020/157699A1 |
Described herein are methods of treating metastatic castration-sensitive prostate cancer with anti-androgens, including but not limited to, 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-
5,7-diazaspiro[3.4]oct-5-yl]-2-fluor...
|
|
WO/2020/155945A1 |
A method for extracting an Indian bread peel composition, comprising: (1) weighing an Indian bread peel sample, adding same to a soaking solvent for soaking, reflowing, and collecting a filtrate; (2) performing vacuum concentration and d...
|
|
WO/2020/158881A1 |
Provided is a topical preparation for the skin or mucosae, the preparation having a superior feel despite using petroleum jelly as a base. The topical preparation, for the skin or mucosae, according to the present invention has: a liqu...
|
|
WO/2020/144561A1 |
Disclosed are pharmaceutical or nutraceutical compositions comprising the peptide having the sequence NMYLPPVPPP PVVPTF or extracts containing it, in admixture with suitable excipients.
|
|
WO/2020/142646A1 |
Methods are described for producing enteroendocrine cells that make and secrete insulin in a subject by co-administering a Foxo1 inhibitor in combination with a Notch inhibitor or ROCK inhibitor, or both. Also described are pharmaceutica...
|
|
WO/2020/136276A1 |
Dry powder inhalation formulation comprising at least one API and a lipid matrix comprising at least one triglyceride chosen in the group consisting of monohydroxystearin, dihydroxystearin, trihydroxystearin and their mixture and its man...
|
|
WO/2020/135476A1 |
A traditional Chinese medicine composition, comprising the following active ingredients in parts by weight: 10-30 parts of root of common monkshood, 5-10 parts of red peony root, 5-10 parts of root of twotooth achyranthes, 5-10 parts of ...
|
|
WO/2020/137687A1 |
[Problem] The purpose of the present invention is to provide a core body temperature improving agent that improves low core body temperatures. [Solution] A core body temperature improvement agent capable of improving low core body temper...
|
|
WO/2020/133063A1 |
Disclosed are application of a small intestinal mucosa active substance in the preparation of food, health products, special clinical diets or medicines, products of the small intestinal mucosa active substance, and a method. The small i...
|
